Just a few years after the introduction of new oral anticoagulants vying to replace warfarin, competition between the novel drugs seems to be based more on pricing, insurance coverage and physician familiarity than on any real differentiation between the products, according to recently published studies.
Already approved for some indications and marketed as Lixiana in Japan, Daiichi Sankyo Co. Ltd.’s once-daily edoxaban is set...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?